Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis

Ionela-Alina Grosu-Creangă; Antigona Carmen Trofor; Radu Adrian Crișan-Dabija; Daniela Robu-Popa; Cristina Mihaela Ghiciuc; Elena Cătălina Lupușoru

doi:10.2478/pneum-2022-0029

References

1. World Health Organization 2021 – Global Tuberculosis Report 2021 ISBN 978-92-4-003702-1 (electronic version). Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021 [Accessed 10th November 2021].
Search in Google Scholar Back to article
2. Cambau E, Drancourt M. Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clinical Microbiology and Infection. 2014;20(3): 196–201. Available from: doi:10.1111/1469-0691.12555.
Open DOI Search in Google Scholar Back to article
3. Wrohan I, Nguyen TA, Nguyen VN, Nguyen BH, Hoang TTT, Nguyen PC, et al. Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: A retrospective cohort study. BMC Infectious Diseases. 2022;22(1): 68. Available from: doi:10.1186/s12879-021-06992-x.
Open DOI Search in Google Scholar Back to article
4. Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. The International Journal Tuberculosis and Lung Disease. 2020;24(5): 547–548.10.5588/ijtld.20.0140
Search in Google Scholar Back to article
5. Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A, et al. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. International Journal of Infectious Diseases. 2021;113(1): S96–S99. Available from: doi:10.1016/j.ijid.2021.02.067.
Open DOI Search in Google Scholar Back to article
6. Katzung BG. Basic and clinical pharmacology, 14th Edition. United States of America: McGraw Hill Education, 2017.
Search in Google Scholar Back to article
7. Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clinical Pharmacology and Therapeutics. 2015;98(4): 387–393. Available from: doi:10.1002/cpt.180.
Open DOI Search in Google Scholar Back to article
8. Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. The International Journal of Tuberculosis and Lung Disease. 1999;3: S301–S308; discussion S317–S321.
Search in Google Scholar Back to article
9. Bendre AD, Peters PJ, Kumar J. Tuberculosis: past, present, and future of the treatment and drug discovery research. Current Research in Pharmacology and Drug Discovery. 2021;2: 100037.10.1016/j.crphar.2021.100037
Search in Google Scholar Back to article
10. WHO. Latent TB infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018 Available from: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1&isAllowed=y. [Accessed 10th November 2021].
Search in Google Scholar Back to article
11. WHO. WHO operational handbook on tuberculosis. Module 4: Treatment – drug resistant tuberculosis treatment. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2020 Available from: https://www.who.int/publications/i/item/9789240006997. WHO 2020. Consultation https://www.who.int/publications-detail-redirect/9789240006997 [Accessed 20th December 2021].
Search in Google Scholar Back to article
12. Gülbay BE, Gürkan ÖU, Yıldız ÖA, Onen ZP, Erkekol FO, Baççioğlu A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine. 2006;100(10): 1834–1842.10.1016/j.rmed.2006.01.014
Search in Google Scholar Back to article
13. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine. 2020;8(4): 383–394. Available from: doi:10.1016/S2213-2600(20)30047-3.
Open DOI Search in Google Scholar Back to article
14. Sun W, Wu Z, Zhou Y, et al. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China. BMC Infect Dis. 2021;21(1): 834. Available from: https://doi.org/10.1186/s12879-021-06553-2.10.1186/s12879-021-06553-2837440834412615
Search in Google Scholar Back to article
15. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. The New England Journal Medicine. 2020;382(10): 893–902. Available from: doi:10.1056/NEJMoa1901814.695564032130813
Open DOI Search in Google Scholar Back to article
16. World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: WHO; 2019 (WHO/CDS/TB/2019.7) Available from: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf [ Accessed 18th December 2021].
Search in Google Scholar Back to article
17. Lièvre M, Cucherat M, Leizorovicz A. Pooling, meta-analysis, and the evaluation of drug safety. Current Controlled Trials in Cardiovascular Medicine. 2002;3(1): 6. Available from: doi:10.1186/1468-6708-3-6.13447811991807
Open DOI Search in Google Scholar Back to article
18. Palma-Alvarez RF, Duque-Yemail J, Ros-Cucurull E, Robles-Martínez M, Perea-Ortueta M, Grau-López L, et al. Quinolone-induced psychosis: An updated review. Actas Españolas de Psiquiatría. 2020;48(3): 126–137.
Search in Google Scholar Back to article
19. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clinical Infectious Diseases. 2008;47(6): 735–743.10.1086/59112618694344
Search in Google Scholar Back to article
20. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opinion on Drug Safety. 2013;12(4): 497–505. Available from: doi:10.1517/14740338.2013.796362.23651367
Open DOI Search in Google Scholar Back to article
21. Sheffield ME, Jones BM, Terrell B, Wagner JL, Bland CM. Influence of probiotics on the development of Clostridioides difficile infection in patients receiving fluoroquinolones. Pharmacy (Basel). 2021;9(3): 141. Available from: doi:10.3390/pharmacy9030141.839616834449745
Open DOI Search in Google Scholar Back to article
22. Arbex MA, de Castro Lima Varella M, de Siqueira HB, de Mello FAF. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second-line drugs. Jornal Brasileiro de Pneumologia. 2010;36(5): 641–656.10.1590/S1806-37132010000500017
Search in Google Scholar Back to article
23. Chide OE, Orisakwe OE. Structural development, haematological immunological and pharmacological effects of quinolones. Recent Patents on Anti-Infective Drug Discovery. 2007;2: 157–168.10.2174/15748910778083266818221172
Search in Google Scholar Back to article
24. Ausi Y, Santoso P, Sunjaya DK, Barliana MI. Between curing and torturing: Burden of adverse reaction in drug-resistant tuberculosis therapy. Patient Preference and Adherence. 2021;15: 2597–2607. Available form: doi:10.2147/ppa.s333111.
Open DOI Search in Google Scholar Back to article
25. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(3): 3–8.10.1159/00005783811549783
Search in Google Scholar Back to article
26. Minardi ML, Fato I, Di Gennaro F, Mosti S, Mastrobattista A, Cerva C, et al. Common and rare hematological manifestations and adverse drug events during treatment of active TB: A state of art. Microorganisms. 2021;9(7): 1477. Available from: doi:10.3390/microorganisms9071477.830468034361913
Open DOI Search in Google Scholar Back to article
27. Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR – and XDR-TB: a multicentre study. The European Respiratory Journal. 2017;49(5): 1700387. Available from: doi:10.1183/13993003.00387-2017.28529205
Open DOI Search in Google Scholar Back to article
28. Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, et al. Safety and efficacy of exposure to bedaquilinedelamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. The European Respiratory Journal. 2018;51: 1702550.10.1183/13993003.02550-2017
Search in Google Scholar Back to article
29. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam University Journal of Medicine. 2020;37(4): 277–285. Available from: doi:10.12701/yujm.2020.00626.
Open DOI Search in Google Scholar Back to article
30. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2002;6(7): 622–627.
Search in Google Scholar Back to article
31. Gupta A, Kumar V, Natarajan S, Singla R. Adverse drug reactions & drug interactions in MDR-TB patients. The Indian Journal of Tuberculosis. 2020;67(4S): S69–S78. Available from: doi:10.1016/j.ijtb.2020.09.027.
Open DOI Search in Google Scholar Back to article
32. Gopal P, Grüber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends in Pharmacological Sciences. 2019;40(12): 930–940. Available from: doi:10.1016/j.tips.2019.10.005.
Open DOI Search in Google Scholar Back to article
33. Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R, et al. Antibacterial and pharmacological evaluation of fluoroquinolones: a chemoinformatics approach. Genomics and Informatics. 2018;16(3): 44–51.10.5808/GI.2018.16.3.44
Search in Google Scholar Back to article
34. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007;15: 352–357.10.1097/MOO.0b013e3282ef772d
Search in Google Scholar Back to article
35. Li Y, Wang F, Wu L, Zhu M, He G, Chen X, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infection and Drug Resistance. 2019;12: 721–731.10.2147/IDR.S195555
Search in Google Scholar Back to article
36. Seaworth BJ. Multidrug-resistant tuberculosis. Infectious Disease Clinics of North America. 2002;16(1):73–105.10.1016/S0891-5520(03)00047-3
Search in Google Scholar Back to article
37. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American thoracic society/centers for disease control and prevention/Infectious diseases society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(4): 603–662.10.1164/rccm.167.4.60312588714
Search in Google Scholar Back to article
38. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clinical Infectious Diseases. 2004;38(11): 1538–1544.10.1086/42074215156439
Search in Google Scholar Back to article
39. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249(2–3): 91–96.10.1016/j.tox.2008.04.01518514377
Search in Google Scholar Back to article
40. Wargo AK, Edwards JD. Aminoglycoside-induced nephrotoxicity. Journal of Pharmacy Practice. 2014;27(6): 573–577.10.1177/089719001454683625199523
Search in Google Scholar Back to article
41. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, et al. Aminoglycoside nephrotoxicity: Modeling, simulation, and control. Antimicrobial Agents and Chemotherapy. 2003;47(3): 1010–1016.10.1128/AAC.47.3.1010-1016.2003
Search in Google Scholar Back to article
42. Jain AK, Sharma P. Ethionamide induced blue vision (cyanopsia): case report. Indian Journal of Tuberculosis. 2020;67(3): 333–335.10.1016/j.ijtb.2019.04.011
Search in Google Scholar Back to article
43. Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Brunton LL, Chabner BA, Knollmann BC. (eds.) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New Delhi: McGraw Hill; 2011. p.1549–1570.
Search in Google Scholar Back to article
44. Zhang Y. The magic bullets and tuberculosis drug targets. Annual Review of Pharmacology and Toxicology. 2005;45: 529–564.10.1146/annurev.pharmtox.45.120403.100120
Search in Google Scholar Back to article
45. Abulfathi AA, Donald PR, Adams K, Svensson EM, Diacon A, Reuter H, et al. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. British Journal Clinical Pharmacology. 2020;86: 2123–2132. Available form: doi:10.1111/bcp.14395.
Open DOI Search in Google Scholar Back to article
46. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. The Lancet. 1946;247(6384): 15–16.10.1016/S0140-6736(46)91185-3
Search in Google Scholar Back to article
47. Weng T, Sun F, Li Y, Chen J, Chen X, Li R, et al. Refining MDRTB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infectious Diseases. 2021;21(1): 183. Available form: doi:10.1186/s12879-021-05870-w.788813733596848
Open DOI Search in Google Scholar Back to article

Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis

References

Paradigm

My account